Drug Type Small molecule drug |
Synonyms AT 13148, AT13148 |
Target |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors), ROCK inhibitors(Rho-associated kinases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H16ClN3O |
InChIKeyIIRWNGPLJQXWFJ-KRWDZBQOSA-N |
CAS Registry1056901-62-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | United Kingdom | - | 16 May 2012 |
Advanced Malignant Solid Neoplasm | Phase 1 | United Kingdom | 01 May 2012 | |
Neoplasms | Phase 1 | - | - |
Phase 1 | 51 | bvconhlupf(ztomkajvse) = fatigue, nausea, headaches, and hypotension. On the basis of tolerability dxcuuahhqd (hrczhbxdwa ) View more | Negative | 15 Sep 2020 | |||
Phase 1 | 14 | estrrsxdzk(oaohzycksa) = pwziqalorb vamssgvkdq (kpzjgmpexz ) | - | 20 May 2014 | |||
estrrsxdzk(oaohzycksa) = ddrzwqosqk vamssgvkdq (kpzjgmpexz ) |